Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen

References

• Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212 - 36; http://dx.doi.org/10.3322/caac.20121; PMID: 21685461
   PubMed Web of Science ®Google Scholar
• Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314:268 - 74; http://dx.doi.org/10.1126/science.1133427; PMID: 16959974
   PubMed Web of Science ®Google Scholar
• Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318:1108 - 13; http://dx.doi.org/10.1126/science.1145720; PMID: 17932254
   PubMed Web of Science ®Google Scholar
• Akashi M, Koeffler HP. Li-Fraumeni syndrome and the role of the p53 tumor suppressor gene in cancer susceptibility. Clin Obstet Gynecol 1998; 41:172 - 99; http://dx.doi.org/10.1097/00003081-199803000-00024; PMID: 9504235
   PubMed Web of Science ®Google Scholar
• Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266:66 - 71; http://dx.doi.org/10.1126/science.7545954; PMID: 7545954
   PubMed Web of Science ®Google Scholar
• Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007; 26:2157 - 65; http://dx.doi.org/10.1038/sj.onc.1210302; PMID: 17401424
   PubMed Web of Science ®Google Scholar
• Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, et al, Breast Cancer Susceptibility Collaboration (UK). ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 2006; 38:873 - 5; http://dx.doi.org/10.1038/ng1837; PMID: 16832357
   PubMed Web of Science ®Google Scholar
• Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378:789 - 92; http://dx.doi.org/10.1038/378789a0; PMID: 8524414
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?. Nat Rev Cancer 2007; 7:545 - 53; http://dx.doi.org/10.1038/nrc2173; PMID: 17585334
   PubMed Web of Science ®Google Scholar
• Carey LA. Through a glass darkly: advances in understanding breast cancer biology, 2000-2010. Clin Breast Cancer 2010; 10:188 - 95; http://dx.doi.org/10.3816/CBC.2010.n.026; PMID: 20497917
   PubMed Web of Science ®Google Scholar
• van ’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530 - 6; http://dx.doi.org/10.1038/415530a; PMID: 11823860
   PubMed Web of Science ®Google Scholar
• Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365:671 - 9; PMID: 15721472
   PubMed Web of Science ®Google Scholar
• Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351:2817 - 26; http://dx.doi.org/10.1056/NEJMoa041588; PMID: 15591335
   PubMed Web of Science ®Google Scholar
• Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007; 25:1239 - 46; http://dx.doi.org/10.1200/JCO.2006.07.1522; PMID: 17401012
   PubMed Web of Science ®Google Scholar
• Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349:2042 - 54; http://dx.doi.org/10.1056/NEJMra023075; PMID: 14627790
   PubMed Web of Science ®Google Scholar
• Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343:1350 - 4; http://dx.doi.org/10.1056/NEJM200011093431901; PMID: 11070098
   PubMed Web of Science ®Google Scholar
• Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008; 358:1118 - 28; http://dx.doi.org/10.1056/NEJMoa0706550; PMID: 18337602
   PubMed Web of Science ®Google Scholar
• Schuebel KE, Chen W, Cope L, Glöckner SC, Suzuki H, Yi JM, et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet 2007; 3:1709 - 23; http://dx.doi.org/10.1371/journal.pgen.0030157; PMID: 17892325
   PubMed Web of Science ®Google Scholar
• Glöckner SC, Dhir M, Yi JM, McGarvey KE, Van Neste L, Louwagie J, et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res 2009; 69:4691 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-08-0142; PMID: 19435926
   PubMed Web of Science ®Google Scholar
• Hoque MO, Kim MS, Ostrow KL, Liu J, Wisman GB, Park HL, et al. Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res 2008; 68:2661 - 70; http://dx.doi.org/10.1158/0008-5472.CAN-07-5913; PMID: 18413733
   PubMed Web of Science ®Google Scholar
• Ordway JM, Budiman MA, Korshunova Y, Maloney RK, Bedell JA, Citek RW, et al. Identification of novel high-frequency DNA methylation changes in breast cancer. PLoS One 2007; 2:e1314; http://dx.doi.org/10.1371/journal.pone.0001314; PMID: 18091988
   PubMed Web of Science ®Google Scholar
• Ostrow KL, Park HL, Hoque MO, Kim MS, Liu J, Argani P, et al. Pharmacologic unmasking of epigenetically silenced genes in breast cancer. Clin Cancer Res 2009; 15:1184 - 91; http://dx.doi.org/10.1158/1078-0432.CCR-08-1304; PMID: 19228724
   PubMed Web of Science ®Google Scholar
• Fujikane T, Nishikawa N, Toyota M, Suzuki H, Nojima M, Maruyama R, et al. Genomic screening for genes upregulated by demethylation revealed novel targets of epigenetic silencing in breast cancer. Breast Cancer Res Treat 2010; 122:699 - 710; http://dx.doi.org/10.1007/s10549-009-0600-1; PMID: 19859801
   PubMed Web of Science ®Google Scholar
• McGarvey KM, Van Neste L, Cope L, Ohm JE, Herman JG, Van Criekinge W, et al. Defining a chromatin pattern that characterizes DNA-hypermethylated genes in colon cancer cells. Cancer Res 2008; 68:5753 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-08-0700; PMID: 18632628
   PubMed Web of Science ®Google Scholar
• Zhang W, Glöckner SC, Guo M, Machida EO, Wang DH, Easwaran H, et al. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res 2008; 68:2764 - 72; http://dx.doi.org/10.1158/0008-5472.CAN-07-6349; PMID: 18413743
   PubMed Web of Science ®Google Scholar
• Hill VK, Ricketts C, Bieche I, Vacher S, Gentle D, Lewis C, et al. Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. Cancer Res 2011; 71:2988 - 99; http://dx.doi.org/10.1158/0008-5472.CAN-10-4026; PMID: 21363912
   PubMed Web of Science ®Google Scholar
• Hoque MO, Feng Q, Toure P, Dem A, Critchlow CW, Hawes SE, et al. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol 2006; 24:4262 - 9; http://dx.doi.org/10.1200/JCO.2005.01.3516; PMID: 16908936
   PubMed Web of Science ®Google Scholar
• Yan PS, Perry MR, Laux DE, Asare AL, Caldwell CW, Huang TH. CpG island arrays: an application toward deciphering epigenetic signatures of breast cancer. Clin Cancer Res 2000; 6:1432 - 8; PMID: 10778974
   PubMed Web of Science ®Google Scholar
• Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002; 416:552 - 6; http://dx.doi.org/10.1038/416552a; PMID: 11932749
   PubMed Web of Science ®Google Scholar
• Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol 1987; 196:261 - 82; http://dx.doi.org/10.1016/0022-2836(87)90689-9; PMID: 3656447
   PubMed Web of Science ®Google Scholar
• Brandes JC, Carraway H, Herman JG. Optimal primer design using the novel primer design program: MSPprimer provides accurate methylation analysis of the ATM promoter. Oncogene 2007; 26:6229 - 37; http://dx.doi.org/10.1038/sj.onc.1210433; PMID: 17384671
   PubMed Web of Science ®Google Scholar
• Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996; 93:9821 - 6; http://dx.doi.org/10.1073/pnas.93.18.9821; PMID: 8790415
   PubMed Web of Science ®Google Scholar